I and Part II assessments, allowing sponsors to submit a unified dossier reviewed simultaneously by all concerned Member States. This new system simplifies procedures but requires robust internal preparedness.

Sponsor Responsibilities Under CTR vs EudraCT

Sponsors operating in the EU must now classify each trial as “CTR-governed” or “EudraCT legacy.” Key responsibilities include:

• CTR: Submission via CTIS, including both scientific (Part I) and ethical (Part II) dossiers, transparency rules application, timeline tracking, and deferral of sensitive data if applicable.
• EudraCT: Continue status updates and summary results submission for trials approved before 31 Jan 2023, with EudraCT number still required for audit trail.

Sponsors are advised to maintain SOPs clearly delineating workflow separation between CTR and EudraCT to avoid compliance lapses. If a sponsor operates multiple ongoing trials under both regulations, dual governance may be necessary, particularly across EU affiliates.

Transparency and Public Disclosure Obligations

CTR introduces a new paradigm of transparency:

• Trial data is proactively published on the public CTIS site
• Sponsors must identify personal and commercially confidential information (CCI)
• Deferral rules exist but require justification and documentation

This contrasts with EudraCT, where only approved protocol summaries and results were eventually published on the EU Clinical Trials Register. Under CTR, real-time postings are visible within a structured disclosure timeline. Failure to meet these obligations may result in public scrutiny, EMA warnings, or compliance findings.

Clinical Trial Phases and Data Posting Requirements

Under CTR, trial phases and their associated disclosure expectations are tightly controlled:

• Phase 1: Subject to transparency with deferral permitted
• Phase 2–4: Full protocol, results, and assessments published unless redacted
• Results Reporting: Mandatory within 12 months of end of trial in EU

This represents a significant shift for sponsors who were previously managing multiple local expectations. A cross-functional CTR implementation team (including RA, clinical ops, legal, and data protection) is now considered best practice.

Transition Strategy: Managing Dual Systems (EudraCT + CTR)

Between 31 Jan 2023 and 30 Jan 2025, sponsors are permitted to initiate trials under either EudraCT (Directive) or CTR (Regulation). After this transition period, all ongoing trials must migrate to CTR/CTIS. Managing this dual system requires:

• Identifying all active EudraCT trials and planning a migration strategy
• Developing dual SOPs and checklists for submission, amendment, and result posting
• Establishing internal trackers for deferrals, Part I/II approvals, and public postings
• Training staff on CTIS user roles, access rights, and mandatory workflows

Many sponsors opt to designate a CTIS coordinator within Regulatory Operations to handle CTIS submissions while legacy roles continue EudraCT monitoring. This division minimizes overlap confusion.

Technical Readiness: CTIS System Access and Validation

CTIS is more than just a submission portal—it is an end-to-end lifecycle management platform. To function effectively within this system, sponsors must:

• Register and validate their organization with EMA’s Organization Management System (OMS)
• Assign user roles via EMA’s Identity Access Management (IAM) portal
• Ensure regulatory staff are trained in document uploading, decision documentation, and result entry
• Install XML-compatible tools to validate CTIS uploads against EMA schema

Delays in user access or incorrect XML formatting can result in rejections or delayed authorizations. Sponsors are advised to conduct internal test runs using non-critical protocols before official CTR submission. For training resources, EMA offers CTIS workshops and helpdesk services at ema.europa.eu.

Compliance Risk Areas and EMA Inspection Trends

EMA and Member State authorities have already conducted inspections under CTR. Early compliance risk signals include:

• Failure to update protocol status in CTIS within required timelines (15 days for certain events)
• Inconsistent or outdated Part II documents such as informed consent forms
• Lack of documentation for deferral justifications or CCI redactions
• Discrepancies between trial master file (TMF) and CTIS posted documents

A sponsor in Belgium was cited in early 2024 for not updating their trial status post-termination, leading to a public compliance finding on the CTIS portal. To avoid such outcomes, sponsors must integrate CTIS checks into their internal audit plans and Quality Management Systems (QMS). Audit-ready dashboards and TMF indexing are critical tools in this respect.

Conclusion

The transition from EudraCT to CTR via CTIS represents the most significant shift in EU clinical trial regulation in decades. While EudraCT still applies to legacy trials until 2025, all sponsors must invest in CTR capabilities today to avoid non-compliance and public transparency failures. From technical access, data governance, cross-functional workflows, and submission planning — CTR demands proactive preparation.

Organizations who master this transition will benefit from faster, harmonized EU approvals, increased public trust, and reduced regulatory friction. To support your CTIS journey, visit PharmaSOP.in for SOP templates or refer to official guidance at EMA’s CTR Portal.